Prescribed Zantac heartburn medicine recall in the UK

Prescribed Zantac heartburn medicine recall in UK - The Mandatory Training Group UK -

Prescribed Zantac heartburn medicine recall in the UK

Prescribed Zantac heartburn medicine recall in the UK.

Prescribed Zantac heartburn medicine recall in UK - The Mandatory Training Group UK -


UK doctors are being told to stop prescribing four types of heartburn medication called Zantac or ranitidine as a “precautionary measure”.

It follows concern in several countries that products may contain an impurity that has been linked to cancer.

The four being recalled are Zantac 150mg/10ml Syrup, Zantac 50mg/2ml Injection, Zantac 150mg Tablets and Zantac 300mg Tablets.

But patients should keep taking their prescribed medicine, officials advise.

The Medicines and Healthcare products Regulatory Agency (MHRA) says the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant N-nitrosodimethylamine (NDMA).

Anyone who is concerned about taking their medication should speak to their doctor or pharmacist.

What is the recall about?

NDMA is classified as a probable human carcinogen (a substance that could cause cancer) on the basis of animal studies. It is present in some foods and in water supplies but is not expected to cause harm when ingested in very low levels.

The MHRA has asked manufacturers to quarantine all products which may contain the active pharmaceutical ingredient (API) that is potentially affected by this issue.

The four in the recall are made by GlaxoSmithKline (GSK).

Over-the-counter products (Zantac 75 Relief (PL 02855/0081 [GSL]) and Zantac 75 Tablets (PL 02855/0082 [P]), which people can buy in pharmacies without a prescription, are produced by a different company and are not affected by the recall.

The MHRA is investigating other ranitidine medicines which may also be affected and will provide updates soon.

Should I be concerned?

Currently, there is no evidence that medicines containing this type of impurity have caused any harm to patients, say experts.

Dr Andrew Gray, from the MHRA, said: “Whilst this action is precautionary, the MHRA takes patient safety very seriously.

“We have asked companies to quarantine batches of potentially affected medicines whilst we investigate and we will take action as necessary, including product recalls where appropriate.

“We have also requested risk assessments from the relevant companies which will include the testing of potentially affected batches.”

A spokesman for GSK said the company initiated a voluntary recall of all Zantac products “as a precautionary measure” and relayed its decision to the MHRA, which issued a UK-wide drug alert on Tuesday.

He added: “GSK is continuing with investigations into the potential source of the NDMA… and have engaged with external laboratories to conduct tests on the API and finished product batches of Zantac.”

Creative Commons Disclosure

This article was published by BBC News. Click here to view the original post.

About The Mandatory Training Group

The Mandatory Training Group is the leading UK provider of accredited healthcare and social care statutory and mandatory training courses, programs and qualifications.

Click on the links below to find out more about our safe handling of medication training courses and programs.

Contact our Support Team on 02476100090 or via Email for more courses relating to the Care Quality Commission (CQC) and other regulatory compliance requirements.

Prescribed Zantac heartburn medicine recall in the UK.

Share this post

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: